Clinical Trials Arena on MSN
Novocure’s Optune Gio fails to show benefit at earlier stage
The Phase III TRIDENT study failed to show statistical significance in OS when Optune Gio was used earlier.
By Sneha S K June 18 (Reuters) - Novocure said on Thursday that a late-stage trial showed early use of its non-invasive cancer therapy did not significantly improve overall survival in patients with ...
Shares in the company fell nearly 25% in premarket trading Thursday morning on the news. (©2018 Novocure. All rights reserved.) Novocure’s tumor-treating electric ...
The life science industry recently gave folks diagnosed with pancreatic cancer the best news this group has received in a very long time. A new treatment option that significantly raises their chances ...
CHICAGO — A medical device made by Novocure that creates electric fields in the lungs via wearable skin patches extended the survival of patients with lung cancer in a clinical trial, researchers ...
ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the global phase 3 TRIDENT clinical trial evaluating the safety and efficacy of ...
Young medical companies with new therapies often navigate a challenging path. That's true today for NovoCure (NASDAQ: NVCR), which makes a wearable device for treating cancer. The average investor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results